MB
RNAC icon

MPM BioImpact’s Cartesian Therapeutics RNAC Stock Holding History

MPM BioImpact’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-380,000
Closed -$3.88M – 47
2025
Q3 		$3.88M Sell
380,000
-306,007
-45% -$3.44M 0.64% 35
2025
Q2 		$7.13M Sell
686,007
-104,772
-13% -$1.12M 1.24% 35
2025
Q1 		$10.4M Buy
790,779
+69,640
+10% +$1.24M 1.79% 24
2024
Q4 		$12.9M Buy
721,139
+91,716
+15% +$1.86M 1.83% 22
2024
Q3 		$10.1M Buy
629,423
+369,727
+142% +$5.78M 1.52% 24
2024
Q2 		$7.01M Buy
+259,696
New +$6.2M 1.09% 32

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MPM BioImpact's RNAC Position: Q4 2025 in Review

MPM BioImpact sold out of Cartesian Therapeutics (RNAC) in Q4 2025, closing a stake of 380,000 shares — an estimated $3.88M sold.

MPM BioImpact first reported a position in RNAC in Q2 2024 and held it in 6 quarters. The position peaked at $12.9M in Q4 2024. 67 funds tracked by Wall St. Rank hold RNAC as of Q4 2025.

  • MPM BioImpact reported no remaining Cartesian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • MPM BioImpact sold 380,000 Cartesian Therapeutics shares in Q4 2025, an estimated $3.88M.
  • MPM BioImpact first reported a position in Cartesian Therapeutics in Q2 2024 and held it in 6 quarters.
  • MPM BioImpact's Cartesian Therapeutics position peaked at $12.9M in Q4 2024.
  • 67 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2025.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.